Cara Therapeutics, a client of Unigene Laboratories, has commenced a Phase I study of its oral proprietary peptide-based, investigational drug, CR845, a novel peripherally-acting kappa opioid agonist in healthy volunteers. The CR845 oral capsules were formulated using Unigene’s validated, proprietary peptide manufacturing technology under a Manufacturing and Clinical Supply Agreement established in May 2011. Ashleigh Palmer, Unigene’s president and chief executive officer, commented...